Covid-19
Scaling up COVID-19 rapid antigen tests: promises and challenges
2 Mar, 2021 | 02:09h | UTCScaling up COVID-19 rapid antigen tests: promises and challenges – The Lancet Infectious Diseases
Review: Cardiovascular biomarkers in patients with COVID-19
2 Mar, 2021 | 02:07h | UTC
Commentary on Twitter
Cardiovascular #biomarkers in patients with #COVID19 – review article by @escardio Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association #ACVC_ESC https://t.co/9Mcx24fX8y#EHJACVC #cardiotwitter #medtwitter pic.twitter.com/y7kD2Oylrj
— European Society of Cardiology Journals (@ESC_Journals) March 1, 2021
Serious bradycardia and Remdesivir for COVID-19: a new safety concern
2 Mar, 2021 | 02:06h | UTC
Commentary on Twitter
⛔A new safety concern⛔
New 🔥 post-marketing study @CMIJournal suggests that the use of remdesivir is significantly associated with an increased risk of reporting serious bradycardia compared with HCQ,LPV/RTV, tocilizumab or glucocorticoids #IDTwitter https://t.co/npLMchifEM— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) February 27, 2021
Systematic Review: Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID‐19
2 Mar, 2021 | 01:54h | UTCSummary: Can symptoms and medical examination accurately diagnose COVID-19? – Cochrane Library
We’ve updated our review on signs and symptoms for diagnosing Covid-19. Now includes evidence on loss of smell or taste #redflag @deeksj @leeflang_m @devymaye @SabineDittrich @jacdinnes https://t.co/P4hBbuL0x9
— Ann Van den Bruel (@annvdbruel) February 24, 2021
Vaccinating the oldest against COVID-19 saves both the most lives and most years of life
2 Mar, 2021 | 02:04h | UTCCommentary: Vaccinating Oldest First for COVID Saves the Most Lives: Study – HealthDay
Commentary on Twitter
The policy of vaccinating the oldest vs covid-19:
Most lives saved and most years of life saved, the latter representing an unexpected extent of life expectancy gainhttps://t.co/KgLrl1j2xt @PNASNews by @jrgoldstein1 and colleagues pic.twitter.com/4MWZRa1i11— Eric Topol (@EricTopol) February 25, 2021
Who gets a COVID-19 vaccine and who pays? The need for economic analysis
2 Mar, 2021 | 02:02h | UTC
Commentary on Twitter
NEW from @CGDev and @idsihealth — experts look at the potential of Health Technology Assessment (HTA) on informing how much #COVID19 vaccine countries should buy, who should pay, and how vaccines can be most effectively delivered.
Read: https://t.co/KuMZSARSEF #GlobalHealth
— Center for Global Development (@CGDev) February 24, 2021
CDC Report: Reduction in severe COVID-19 following the implementation of a national vaccination program in Israel
28 Feb, 2021 | 21:54h | UTCCommentary: Israeli data suggest mass vaccinations led to drop in severe Covid cases, CDC study finds – CNBC
Commentary on Twitter
A new @CDCMMWR from Israel shows preliminary evidence of the effectiveness of vaccination in preventing severe cases of #COVID19. Vaccination among people who are eligible to receive a COVID-19 vaccine can potentially reduce severe disease from COVID-19. https://t.co/CaUAXRVaS4 pic.twitter.com/GyaulMONpZ
— CDC (@CDCgov) February 26, 2021
M-A: Treatment with convalescent plasma is not associated with better outcomes in patients with Covid-19
28 Feb, 2021 | 21:51h | UTCEditorial: Emerging Lessons From COVID-19 for the US Clinical Research Enterprise
Commentary on Twitter
Just out: Our meta-analysis in @JAMA_current
"Among patients with COVID-19, treatment with convalescent plasma compared with control was not associated with improved survival or other positive clinical outcomes"https://t.co/tRqpd9v67m
— Lars G. Hemkens (@LGHemkens) February 26, 2021
CDC Study: Suspected SARS-CoV-2 reinfections in a skilled nursing facility
28 Feb, 2021 | 21:55h | UTCCommentaries: Possible SARS-CoV-2 Reinfection Described at Skilled Nursing Facility – HealthDay AND Reinfections could be more likely among those with a mild first case of COVID-19: case study – CTV News
Commentary on Twitter (thread – Click for more)
📌CDC report: Asymptomatic or mildly symptomatic infections don't always produce sufficient immune response to prevent reinfection. Report of nursing facility found 5 people reinfected ~3 months after initial infection. All 5 had more severe symptoms 2nd time around, one death🧵 pic.twitter.com/m9ix9XJolA
— Dr. Ali Nouri (@AliNouriPhD) February 28, 2021
Short Review: SARS-CoV-2 Vaccines
28 Feb, 2021 | 21:52h | UTCAuthor interview: Coronavirus Vaccines—An Overview
Check out the Table ins this #SARSCoV2 Vaccine Overview – everything you wanted to know about upcoming vaccines – Oxford/AZ, Sputnik, Sinovac, more! https://t.co/TWbgfSKBIP
— JAMA (@JAMA_current) February 26, 2021
Studies: Single dose of vaccine acts as ‘booster’ in those with prior COVID-19 infection
28 Feb, 2021 | 21:49h | UTCStudy 1: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals – The Lancet
Commentary on Twitter (thread – click for more)
New on 1-dose @Pfizer vaccine after prior covid
"We show that individuals with previous #SARSCoV2 infection generate strong humoral and cellular responses to one dose of BNT162b2 vaccine, with evidence of high titres of in-vitro live virus neutralisation"https://t.co/2G7TRu57OI pic.twitter.com/sIdB0VarqB— Eric Topol (@EricTopol) February 25, 2021
Identification of 3 clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19
28 Feb, 2021 | 21:45h | UTCInvited Commentary: Anticipating outcomes for patients with COVID-19 and identifying prognosis patterns
Commentary on Twitter
Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19 https://t.co/kLtzmF5ZWI 📣 These results might help to better classify patients for clinical management #COVID@SPAIN #COVID@HULP pic.twitter.com/ZVaMuUDfnL
— Alberto M. Borobia (@borobia_am) February 24, 2021
Spain to give just one vaccine dose to under 55-year olds who had COVID-19
28 Feb, 2021 | 21:47h | UTCSpain to give just one vaccine dose to under 55-year olds who had COVID-19 – Reuters
Related: Is One Vaccine Dose Enough After COVID-19 Infection? – NIH Director’s Blog AND France’s health authority recommends single vaccine shot for people who have had COVID-19
Long Read | 5 Pandemic Mistakes We Keep Repeating
28 Feb, 2021 | 21:43h | UTC5 Pandemic Mistakes We Keep Repeating – The Atlantic (a few articles per month are free)
Editorial | Twenty Lessons from 2020: With a Focus on the ICU Perspective
28 Feb, 2021 | 21:44h | UTCTwenty Lessons from 2020: With a Focus on the ICU Perspective – ICU Management & Practice
2 Case Series and Guidance| Lymphadenopathy in COVID-19 Vaccine Recipients
28 Feb, 2021 | 21:42h | UTCCase series: Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncology Patients – Radiology
Related case series in women without cancer: Coronavirus Disease (COVID-19) Vaccination Associated Axillary Adenopathy: Imaging Findings and Follow-Up Recommendations in 23 Women – American Journal of Roentgenology
Related guidance 1: Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel – Radiology
Related guidance 2: Mitigating the Impact of Coronavirus Disease (COVID-19) Vaccinations on Patients Undergoing Breast Imaging Examinations: A Pragmatic Approach – American Journal of Roentgenology AND Commentary: What to do when a mammogram shows swollen lymph nodes in women just vaccinated for COVID – Massachusetts General Hospital
Commentary: COVID-19 vaccine affects imaging results, researchers warn – AuntMinnie (free registration required)
CDC studies on superspreading events at fitness facilities
26 Feb, 2021 | 08:44h | UTCCommentaries: Going maskless is a key factor in Covid-19 outbreaks at gyms, studies say – CNN AND A Chicago gym saw dozens of COVID-19 cases after infected people attended HIIT classes without masks – Insider
Conflicting results from 2 randomized trials testing Tocilizumab for Covid-19
26 Feb, 2021 | 08:48h | UTC
Commentary on Twitter
Why do 2 randomized trials of tocilizumab, an interleukin-6 blocker, for severe covid-19, have opposite results?
Today @NEJMhttps://t.co/g8LCrhhpLyhttps://t.co/BcN3wOwsl0 pic.twitter.com/sLrQUYI1pf— Eric Topol (@EricTopol) February 25, 2021
WHO Report: Preparing for Long COVID 2021
26 Feb, 2021 | 08:46h | UTCIn the wake of the pandemic: preparing for Long COVID (2021) – World Health Organization
Commentaries: Long COVID sufferer still has disease’s debilitating symptoms nearly a year after first falling ill – EuroNews AND Debilitating ‘long-COVID’ may have severe health, social impacts: WHO – Reuters
Related: Dr. Fauci says new data suggests ‘long’ Covid symptoms can last up to 9 months – CNBC
New protocol tested SARS-CoV-2 positivity on day 9 among quarantined student contacts of confirmed cases, resulting in safe reduction in loss of instructional time
26 Feb, 2021 | 08:42h | UTCCommentary: Is the CDC 10-day COVID-19 quarantine guideline enough? – News Medical
Commentary on Twitter
In this study of a 9-day testing protocol for student contacts of confirmed #COVID19 cases in 1 Florida county, a reduction in loss of instructional time was found that was less than what would have occurred with 14-day quarantine https://t.co/YPft2oAvYk
— JAMA (@JAMA_current) February 19, 2021
Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19
26 Feb, 2021 | 08:43h | UTCCommentary: Studies help discern severe COVID from related kids’ syndrome – CIDRAP
Commentary on Twitter
In this case series using national MIS-C registry data, kids w MIS-C were younger (6-12 y), more likely to be non-Hispanic Black, & have severe CV or mucocutaneous involvement and more extreme inflammation vs kids w severe #COVID19 https://t.co/jmCCDPXLmf @BostonChildrens
— JAMA (@JAMA_current) February 25, 2021
Real-world data confirms Pfizer-BioNTech vaccine effectiveness
25 Feb, 2021 | 09:09h | UTCAudio Interview: The Real-World Effectiveness of Covid-19 Vaccination – New England Journal of Medicine
Commentaries: Real-world trial of Pfizer COVID vaccine finds high 2-dose, good 1-dose protection – CIDRAP AND Pfizer-BioNTech vaccine performs as well in the real world as in clinical trials, new study concludes – STAT AND In boost for COVID-19 battle, Pfizer vaccine found 94% effective in real world – Reuters AND Expert reaction to NEJM paper on Pfizer-BioNTech vaccine roll-out in Israel and COVID-19 outcomes – Science Media Centre
Commentary on Twitter (thread – click for more)
1/
We've just confirmed the effectiveness of the Pfizer-BioNTech vaccine outside of randomized trials.Details @NEJM: https://t.co/POgXK8owvM
Yes, great news, but let's talk about methodological issues that arise when using #observational data to estimate vaccine effectiveness.
— Miguel Hernán (@_MiguelHernan) February 24, 2021
Study finds increased COVID-19 mortality among adults with Down syndrome
26 Feb, 2021 | 08:39h | UTCCommentaries: Adults with Down syndrome 3 times more likely to die of COVID, study finds – CIDRAP AND International study finds increased COVID-19 mortality among adults with Down syndrome – Case Western Reserve University
Related: COVID-19 is 10 times deadlier for people with Down syndrome, raising calls for early vaccination – Science (a few articles per month are free)
COVID-19 hospitalizations attributable to cardiometabolic conditions
26 Feb, 2021 | 08:40h | UTCCommentary: Study estimates two-thirds of COVID-19 hospitalizations due to four conditions – Tufts University
Commentary on Twitter
https://twitter.com/Dmozaffarian/status/1364993823370338312
Opinion – Catching COVID from surfaces is very unlikely. So perhaps we can ease up on the disinfecting
26 Feb, 2021 | 08:38h | UTCRelated: Coronavirus is in the air — there’s too much focus on surfaces – Nature AND COVID-19 rarely spreads through surfaces. So why are we still deep cleaning? – Nature